' INTRODUCTION
According to the WHO, 1 1.7 million people died from tuberculosis (TB) in 2009 and more than 2 billion people (constituting one-third of the world's population) are infected with TB. Among the 9.4 million new TB cases reported in 2009, an estimated 1.1À1.2 million (11À13%) suffer from HIV coinfection. Hence, TB, a contagious infectious disease, is regarded as the leading cause of death due to an infectious agent among adults worldwide and a major threat to global health. 2 The disease establishes mainly in the pulmonary system and is caused by some mycobacteria of the Mycobacterium tuberculosis complex, predominantly Mycobacterium tuberculosis. 3 Active TB is treated by chemotherapy with so-called first-line drugs. 4À6 From the many trials conducted in the past 50À 60 years, two standard regimens emerged which are recommended by the WHO and consist of a two-month daily treatment of either isoniazid, rifampin, pyrazinamide, and streptomycin or isoniazid, rifampin, pyrazinamide, and ethambutol, followed by further four months daily or intermittent doses of isoniazid and rifampin. Unfortunately, the long treatment times and the side effects 7 of the drugs (especially hepatotoxicity) lead to a high proportion of noncompliance patients. This and the rise of the HIV pandemic 8 in the early 1980s led to the emergence of multidrug resistant 9 (MDR) and, more recently, even extensively drug resistant 10 (XDR) strains. MDR-TB is defined as resistance to the action of at least isoniazid and rifampin, and its treatment requires the inclusion of so-called second-line drugs such as aminoglycosides, fluoroquinolones, and second-line bacteriostatics. XDR bacteria are MDR and also resistant to fluoroquinolones and at least one injectable antibiotic. The XDR-tuberculosis is virtually untreatable. The increasing incidences of MDR-and XDR-tuberculosis urgently demand novel drugs for therapy of tuberculosis. The side-effects of current drugs, the high costs of second-line drugs, and the lack of well-established guidelines for the treatment of MDR-TB and XDR-TB require alternative approaches to target tuberculosis. 11, 12 Traditionally, the only known pathway for de novo synthesis of thymidylate which is essential for most eubacteria, plants, and eukaryotic cells was by thymidylate synthase (TS or ThyA). 13 This enzyme catalyzes the reductive methylation of 2 0 -deoxyuridine-5 0 -monophosphate (dUMP) to 2 0 -deoxythymidine-5 0monophosphate using R-N 5 -N 10 -methylene-5,6,7,8-tetrahydrofolate (CH 2 THF) as a methylene and hydride donor, resulting in the formation of 7,8-dihydrofolate (DHF). In the classical ThyA cycle, formation of thymidylate must be coupled with reduction of DHF to THF catalyzed by dihydrofolate reductase (DHFR) and remethylenation by serinehydroxymethyl transferase (SHMT).
However, it has been shown that several microorganisms lack the genes encoding for ThyA and DHFR but are still fully viable in thymidine-deficient media. This led to the discovery of the ThyX gene, which encodes for the ThyX protein, a flavin-dependent Received: April 19, 2011 ABSTRACT: A series of 5-substituted 2 0 -deoxyuridine monophosphate analogues has been synthesized and evaluated as potential inhibitors of mycobacterial ThyX, a novel flavindependent thymidylate synthase in Mycobacterium tuberculosis. A systematic SAR study led to the identification of compound 5a, displaying an IC 50 value against mycobacterial ThyX of 0.91 μM. This derivative lacks activity against the classical mycobacterial thymidylate synthase ThyA (IC 50 > 50 μM) and represents the first example of a selective mycobacterial FDTS inhibitor. thymidylate synthase (FDTS) which is rare in eukaryotes and absent in humans. 14 ThyX uses CH 2 THF only as one-carbon donor, whereas reduced flavin adenine dinucleotide (FADH 2 ) serves as a hydride donor. Members of the ThyX family are NAD(P)H-oxidases because catalysis requires the presence of NAD(P)H to furnish sufficient amounts of FADH 2 via reduction of FAD. Furthermore, ThyX shows no structural similarity with ThyA 15 and there is no sequence similarity between ThyA and ThyX proteins, allowing the design of selective ThyX-inhibitors as a novel approach to target tuberculosis. While some pathogens solely rely on ThyX, genetic analysis revealed that M. tuberculosis carries genes encoding for ThyA, ThyX, and DHFR. 14 Transposon site hybridization studies have shown that the ThyX gene is required for mycobacterial growth and survival within macrophages. 16, 17 Nonetheless, it remains unclear under which conditions either gene is activated. Steady-state kinetic analyses of M. tuberculosis revealed that dTMP-synthesis proceeds with very low catalytic rates in both enzymes, thereby suggesting that the true biological substrates still remain to be found. 18 These findings may be in accordance with the extremely low growth rates of M. tuberculosis and could be an indicator for downregulation of dTMP-production.
In the past few years, several studies to reveal the biochemical reaction mechanism were documented in literature. 19, 20 Initially, an active site catalytic serine was assumed to nucleophilically attack C-6 of dUMP in a Michael-type reaction to give rise to an enolate at C-4 and C-5, which in turn attacks the iminium ion of CH 2 THF to form the new CÀC bond in dTMP. This dUMPÀCH 2 THF adduct subsequently undergoes β-elimination to install an exo-methylene bond between C-5 and C-7, which is reduced by FADH 2 in the final step to yield dTMP.
However, the following facts led to the supersession of this mechanism: (i) The active site serine is too far away from the C-6 of dUMP, as shown by Sampathkumar et al., who provided a crystal structure 21 of Mtb-ThyX in complex with the substrate analogue 5-Br dUMP and FAD, and only conformational changes in the enzyme would be able to lead to nucleophilic catalysis. (ii) No general base is located near this putative serine which would be required to enhance its otherwise too weak nucleophilicity. (iii) Point mutation studies in Thermotoga maritima have shown that the enzyme was still active after mutation of this serine to either an alanine or cysteine. Recently, Koehn et al. performed the reaction in 99% D 2 O which resulted in incorporation of deuterium in the 6-position. These new intriguing findings led to the suggestion of an alternative reaction mechanism 22 (Scheme 1) which contains the following two distinctive key steps: (i) a hydride equivalent is transferred directly from FADH 2 to the C-6 of dUMP (part 2, step 2) and (ii) an unusual 1,3-hydride shift from C-6 to the exo-methylene C-7 in the last step furnishes dTMP (part 3, step 5). Steps 3 and 4 correspond to the previously proposed mechanism and are considered as logical on the mechanistic pathway toward dTMP. An alternative additionÀelimination mechanism involved in the last step could be ruled out when the reaction was performed using 6D-dUMP in H 2 O because the formation of nondeuterated dTMP could not be observed.
Although ThyX is an attractive target for antimycobacterial drug design, the only known inhibitors are 5-F and 5-BrdUMP. 23 However, both are known to act as human ThyA inhibitors and are therefore of no interest for antibacterial therapy. 24À28 Up to now, no selective inhibitors of mycobacterial FDTS are known in literature. In this paper, we describe the synthesis
Scheme 1. Current Biochemical Reaction Mechanism Involving Direct Hydride Transfer and 1,3-Hydride Shift
Journal of Medicinal Chemistry ARTICLE tuning reaction conditions, it was found that successful cross coupling could be achieved with CsF as base in a mixture of DMF and water as solvent (Scheme 3). Under these reaction circumstances, only small amounts of 2 0 -deoxyuridine were detected. Phosphorylation of compounds 9aÀb afforded the 5-aryl-2 0 -dUMP analogues 2aÀb.
Long-chain acetylenic compounds 3aÀb have been synthesized via palladium-catalyzed Sonogashira cross-coupling of suitable acetylenes with unprotected 5-iodo nucleosides as the key step (Scheme 4). 35, 36 Compounds 10a and 10b were accessible from unprotected 5-iodo-2 0 -deoxyuridine 7a and 1-(β-D-arabinofuranosyl)-5-iodoracil 7b, respectively, by Sonogashira cross-coupling with 1-dodecyne with a slightly modified workup than the one described in the literature. Yoshikawa phosphorylation 37,38 (POCl 3 /proton sponge/trimethyl phosphate) finally furnished compounds 3a and 3b (Scheme 4). The arabino-based compounds were synthesized from 1-(β-Darabinofuranosyl)-5-iodoracil, 39 7b, which was prepared by reaction of 1-(β-D-arabinofuranosyl)uracil 39, 40 with I 2 in HNO 3 /CHCl 3 .
For the introduction of an amide functionality into this long chain, acetylated 5-iodo nucleosides 11a 29 and 11b 41, 42 were used as starting material (Scheme 5). For the synthesis of derivatives 4a and 4b, bearing an N-butyl-6-heptynamide chain, compounds 11a and 11b were subjected to Pd-catalyzed crosscoupling with 6-heptynoic acid, 43 followed by DIC/HOBt mediated coupling with n-butylamine. 44 Deprotection of the acetyl groups under alkaline conditions, 29 followed by phosphorylation, yielded the desired final compounds 4a and 4b. On the other hand, the synthesis of 5-propargylamide derivatives 5aÀd and 6aÀb was performed in a divergent manner. The acetylene moieties were synthesized through condensation reaction of propargylamine with suitable acyl chlorides, yielding 15aÀd as shown in Scheme 6. 45 The introduction of the amide-containing terminal acetylenes 15aÀd at position 5 of the uracil ring was achieved via a Sonogashira cross-coupling, followed by deacetylation affording nucleoside analogues 18aÀd (Scheme 7).
Phosphorylation of derivative 18a was problematic. The standard method previously used (POCl 3 /proton sponge/trimethyl phosphate) only gave unsatisfactory results with low yields and difficult purification due to the presence of side products. However, repeated purification (flash chromatography and HPLC) led to the isolation of the pure nucleoside 
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ARTICLE monophosphate derivative 5a. For the phosphorylation of derivatives 18bÀd, the protocol employed by Sowa and Ouchi 33, 46 was evaluated in which the addition of H 2 O to the reaction mixture was reported to enhance the reaction rate. Because of the poor solubility of derivatives 18bÀd in CH 3 CN, a mixture of acetonitrile and trimethyl phosphate was used as solvent. Unfortunately, these reaction conditions (POCl 3 , pyridine, H 2 O in CH 3 CN/PO(OMe) 3 ) were not compatible with the acetylenic group. However, the desired analogues 5b and 5c could be obtained in 96% and 92% purity, respectively, albeit only after a second HPLC purification step. In the case of the desired phenacylamide 5d, considerable amounts of the corresponding keto compound 19, due to hydration of the triple bond, were identified by NMR spectroscopy (Scheme 7). The 1 H NMR spectrum shows two distinct singlets at δ = 7.98 and 8.36 ppm, which were assigned to H-6 in derivatives 5d and 19 in a ratio of 3.26:1, respectively. Furthermore, as expected, the 13 C NMR spectrum shows a clear peak at δ = 199.2 ppm for the ketocarbonyl group, whereas both amide carbonyl peaks of 5d and 19 overlap at δ = 174.2. These findings were confirmed by mass Attempts to separate the desired acetylenic compound from its hydrated form by RP-HPLC were unsuccessful, and therefore alternatives were sought. Compound 18d was coupled with dibenzyl phosphate under Mitsunobu conditions 47 (PPh 3 , DIAD, THF), furnishing the corresponding nucleoside dibenzyl phosphate triester 20. To our disappointment, TMSI-mediated debenzylation 48 equally resulted in an inseparable mixture of 5d and 19 in a ratio of 2.14:1 according to 1 H NMR spectroscopy.
Finally the problem has been solved by using the method of Tener. 49 Thus, 5-iodo-3 0 -O-acetyl-2 0 -deoxyuridine 22, 50À52 prepared in three steps from 5-iodo-2 0 -deoxyuridine 7a (tritylation, acetylation, and detritylation), was coupled with acetylene 15d, yielding 3 0 -O-acetylated derivative 23. DCC-coupling of 23 with 2-cyanoethyl phosphate (pyridinium salt) in anhydrous pyridine, followed by deprotection with 1 M NaOH at 100°C for a few minutes, finally gave pure 5d after purification, however in only 16% yield (Scheme 8). The same strategy was used for the synthesis of dUMP derivatives with sulfonamide and ureacontaining acetylene moieties. Reaction of sodium 1-heptanesulfonate in neat thionyl chloride, 53 followed by condensation of the resulting sulfonyl chloride with propargylamine, 54 furnished acetylene 16 (Scheme 6). Similarly, condensation of propargylamine with hexyl isocyanate yielded acetylenic urea 17. 55 Crosscoupling reaction of 22 with 16 proceeded smoothly, affording compound 24, whereas the corresponding urea derivative 25 could not be obtained in pure form but was used in the subsequent phosphorylation step without any further attempt of purification. Addition of HOBt (1 equiv) did not lead to any significant improvement; sulfonamide monophosphate 6a was obtained in 11% yield. For the synthesis of urea monophosphate 6b, the reaction was carried out at 40°C together with the addition of HOBt (1 equiv). Again, no substantial increase in yield of the desired product (9%) could be achieved (Scheme 8).
Biological Evaluation and StructureÀActivity Relationship Study. Compounds were evaluated for their inhibitory activity against mycobacterial ThyX and ThyA. Cloning of the ThyX gene, protein expression, and purification was done as published previously. 21 The inhibition of ThyX-catalyzed dTMP synthesis was measured in a standard radioactive assay 56,57 using purified ThyX-protein and [5-3 H]-dUMP as a radiolabeled substrate. The amount of tritiated water released during the reaction was measured by liquid scintillation counting. The thyA gene was expressed in E. coli and the expressed His(6)-tagged enzymes were purified by nickel-chelate chromatography. The inhibition of dTMP-synthesis by ThyA was measured in a standard photometric assay 58 on a purified ThyA-protein. The extent of inhibition found is based on a decrease of absorption of DHF (which is formed during the biochemical transformation) at 340 nm in the presence of an inhibitor (see Experimental Section).
The crystal structure 21 of the ThyX-FAD-5-BrdUMP complex shows that the substrate analogue is buried completely in a deep pocket. The oxygen atoms of the phosphate moiety as well as the nitrogen and oxygen atoms of the pyrimidine ring have crucial interactions with numerous highly conserved active site residues, 
ARTICLE notably arginine, glutamic acid, and aspartic acid. As this 5 0 -Omonophosphate group is critical for binding of 5-Br-dUMP, all synthesized nucleosides within this study have been phosphorylated, affording the corresponding nucleotides that have been evaluated as potential mycobacterial ThyX and ThyA inhibitors. Furthermore, the pyrimidine ring of 5-BrdUMP and the isoalloxazine ring of FAD are close enough to interact via hydrogen bonds and π-stacking. Therefore, the pyrimide ring system of dUMP has been kept intact in the search for novel mycobacterial ThyX inhibitors. The C-5 position of dUMP has been subjected to extensive structural modifications using human ThyA as drug target. In this paper, a similar strategy was followed in order to discover novel mycobacterial ThyX inhibitors based on a dUMP scaffold. Compounds were initially evaluated at a concentration of 50 μM in the ThyX as well as in the ThyA assay. Compounds displaying more than 50% inhibition were subjected to do-seÀresponse curves in order to determine IC 50 values. In both assays, 5-F dUMP was included as reference compound and positive control.
The SAR study started with the exploration of relatively small modifications at the C-5-position of the uracil base. Introduction of a cyanovinyl moiety in compound 1 confers good inhibitory activity of mycobacterial ThyX ( Table 1 , IC 50 = 7.4 μM), although no inhibitory effect on mycobacterial ThyA could be observed.
To probe if ThyX can accommodate sterically more demanding substituents at position 5, aryl groups were introduced via Suzuki cross-coupling reactions. The 5-(4-fluorophenyl) analogue 2a exhibits good activity against ThyX (IC 50 = 10 μM), whereas no activity could be determined against ThyA. On the other hand, the 5-(3-methoxyphenyl) analogue 2b shows no activity against both enzymes. It indicates that the nature of the substitution pattern on the phenyl ring has a large influence on the biological activity.
Recently, Johar et al. disclosed arabinonucleoside analogues with a long alkynyl side chain at the 5-position of the uracil moiety that exhibited high levels of antimycobacterial activity in vitro (MIC 90 = 1À5 μg/mL). 59 This observation prompted us to study the effect of a long-chain alkynyl group at C-5 of uridylate on mycobacterial ThyX and ThyA activity. Indeed, 5-dodecynyl-dUMP 3a exhibits moderate ThyX inhibition (IC 50 = 28 μM) but has no effect on ThyA. The corresponding arabino analogue 3b completely lacks activity against both enzymes.
To further explore the SAR, functional groups were introduced into the alkyl chain of derivatives 3a and 3b. The insertion of an amide group in the center of the long alkyl chain afforded compound 4a, which was 3-fold more potent in the ThyX assay when compared with its long-chain analogue 3a. To our disappointment, again, the corresponding arabino congener 4b was completely devoid of thymidylate synthase inhibitory activity (IC 50 > 50 μM). Consequently, any further effort on the synthesis of corresponding arabino derivatives was discontinued and, in subsequent studies, we solely focused on the design and synthesis of dUMP analogues. Shifting the amide functional group closer toward the nucleobase furnished propargylamide derivative 5a, which is 1 order of magnitude more potent (IC 50 = 0.9 μM) than its congener 4a.
To probe the influence of the arm length, the total number of carbon atoms of the alkynyl chain of 5a (12 carbon atom) was decreased to a total number of 10 (compound 5b) and 8 atoms (compound 5c), resulting in a 10-to 30-fold decrease of ThyX inhibition, respectively. Similarly, the presence of a phenyl ring in N-propargyl phenacylamide derivative 5d led to a decreased ThyX inhibitory activity, displaying IC 50 values of 7.3 μM. None of these derivatives shows any appreciable ThyA inhibition.
A long chain consisting of 12 carbon atoms turned out to be optimal for ThyX inhibition. Therefore, the total lengths of 12 atoms, as well as the propargylamine moiety, were preserved and the functional group was modified in a further round of optimization. The amide group of compound 5a was replaced by a sulfonamide moiety and a urea functionality, affording compounds 6a and 6b, respectively. Both analogues show a 5-fold drop in ThyX inhibition when compared to the amide congener 5a and completely lack activity against ThyA.
' CONCLUSION
The increasing incidences of resistant M. tuberculosis bacteria urgently demand novel drugs for therapy of tuberculosis. However, no new anti-TBC drugs have been brought to the market in the last 30 years. The last drug with a new mechanism of action approved for TB was rifampicin (which was already discovered in 1963). Therefore, there is an urgent need for new antimycobacterial drugs with new modes of action to potentially avoid crossresistance. In this paper, mycobacterial ThyX has been selected as a promising target for the development of novel antibacterial drugs. Starting from the natural substrate, dUMP, a SAR study was carried out in which structural variation at C-5 of the uracil moiety was introduced. This work led to the discovery of a novel series of 5-alkynyl dUMP analogues from which the most potent congener (compound 5a) displays an IC 50 value of 0.91 μM against ThyX. The high polarity of this compound makes it very unlikely that it will be able to cross the cell membrane of M. tuberculosis and therefore it has not been tested for its antimicrobial activity. Compound 5a completely lacks activity against mycobacterial ThyA. To our knowledge, this is the first time a selective mycobacterial FDTS inhibitor is reported. Up to now, we have no rationale to explain the observed selectivity. Cocrystallization of compound 5a with the mycobacterial ThyX enzyme should reveal the binding mode of compound 5a and might explain the selective mycobacterial ThyX inhibition. Although compound 5a shows promising activity against the ThyX enzyme, the presence of the phosphate moiety hampers its further development. Further medicinal chemistry efforts will be necessary to improve its drug-like characteristics in order to have access to compounds which are useful for testing in a bacterial assay. 29 7a (250 mg, 0.71 mmol) was dissolved in anhydrous DMF (10 mL), and the solution was flushed with nitrogen gas. To the solution were added acrylonitrile (468 μL, 7.1 mmol), tributylamine (185 μL, 0.78 mmol), and tetrakis(triphenylphosphine)palladium(0) (81 mg, 0.07 mmol), and the reaction mixture was heated at 80°C for 9 h. The solution was evaporated in vacuo and purified using silica gel column chromatography (DCM/MeOH = 97:3f95:5) yielding compound 9 (116 mg, 59%). 1 General Procedure for the Suzuki Reaction of 5-Iodonucleosides 7aÀb with Various Boronic Acids. 5-Iodo-2 0deoxyuridine 29 7a (250 mg, 0.71 mmol) (or 5-iodoracil 1-β-D-arabinofuranoside 7b, 250 mg, 0.67 mmol) was dissolved in DMF (7.5 mL) and H 2 O (3.75 mL). To the solution were added cesium fluoride (268 mg, 1.76 mmol) and a boronic acid (0.85 mmol), whereupon nitrogen gas was passed through the solution for 5 min. Tetrakis(triphenylphosphine)palladium(0) (81 mg, 0.07 mmol) was added, and the reaction mixture was heated at 60°C until the reaction was complete (determined by TLC). The crude mixture was evaporated in vacuo and purified using silica gel column chromatography (DCM/MeOH = 98:2f90:10), yielding title compounds 9aÀb.
5-
5-(4-Fluorophenyl)-2 0 -deoxyuridine (9a). This compound was prepared according to the general procedure described above starting from 7a using 4-fluorophenylboronic acid (119 mg), yielding compound 9a (178 mg, 78%). 1 13 3 0 ,5 0 -di-O-Acetyl-2 0 -deoxyuridine-5-heptynoic Acid (12a).
Compound 11a (1.68 g, 3.83 mmol), Pd(PPh 3 ) 4 (433 mg, 0.382 mmol), and CuI (147 mg, 0.764 mmol) were dissolved in anhydrous DMF (20 mL) under an Ar atmosphere, and DIPEA (1.32 mL, 7.67 mmol) and heptynoic acid (1.45 mL, 11.50 mmol) were then added. After being stirred at rt for 22 h, the solvent was evaporated and coevaporated with xylene. The residue was taken up in DCM/MeOH = 1:1 (40 mL), BioRad XG-X8 (HCO 3 À -form) resin was added, and the mixture was stirred at rt for 30 min. After filtration of the resin and evaporation of the solvents, the crude residue was taken up in EtOAc (70 mL), and the organic layer was washed with brine (3 Â 70 mL), dried over MgSO 4 , and evaporated. The residue was purified by silica gel column chromatography (heptane/EtOAc = 2:3 containing 1% formic acid), and early and late fractions were subjected to a second column using the same eluent to yield compound 12a (783 mg, 47%) as an off-white solid. 1 After being stirred at rt overnight, the solvent was evaporated and coevaporated with xylene. The residue was taken up in DCM/MeOH = 1:1 (40 mL), BioRad XG-X8 (HCO 3 À -form) resin was added, and the mixture was stirred at rt for 30 min. After filtration of the resin and evaporation of the solvents the crude residue was taken up in EtOAc (80 mL), and the organic layer was washed with brine (3 Â 80 mL), dried over MgSO 4 , and evaporated. The residue was purified by silica gel column chromatography (heptane/EtOAc = 2:3 containing 1% formic acid), and early and late fractions were subjected to a second column using the same eluent to yield compound 12b (1.04 g, 52%) as an offwhite solid. 1 13 HOBt (124 mg, 0.924 mmol) in anhydrous DCM (13 mL) under an Ar atmosphere was added n-butylamine (92 μL, 0.924 mmol), and the mixture was cooled to 0°C. DIC (125 μL, 0.807 mmol) was added, and the reaction mixture was stirred at 0°C for 1 h and at rt for 5 h. The solvent was evaporated and the residue taken up in EtOAc (25 mL). The organic layer was washed with satd NaHCO 3 (3 Â 20 mL), dried over MgSO 4 , and evaporated. The residue was purified by silica gel column chromatography (heptane/EtOAc = 1:3 containing 1% formic acid), which gave compound 13a (321 mg, 81%) as an off-white solid. 1 3 .03 (m, 2H, CH 2 NH), 2.53À2.28 (m, 2H, H-2 0 ), 2.37 (t, 2H, J = 6.9 Hz, R-CH 2 ), 2.11À2.03 (m, 8H, 2 Â CH 3 and CH 2 CO), 1.65À1.21 (m, 8H, 4 Â CH 2 ), 0.87 (t, 3H, J = 7.2 Hz). 13 . 13 13 
1-β-D-Arabinofuranosyluracil-5-(N-butyl)heptynamide (14b).
Compound 13b (303 mg, 0.551 mmol) was dissolved in dry MeOH (8 mL), NaOMe (30%-solution in MeOH, 152 μL, 0.8 mmol) was added, and the reaction mixture was stirred for 1 h at rt under an Ar atmosphere. The solution was neutralized with Dowex 50WX-8 resin (H þ -form), and the resin was filtered off and washed with MeOH. After evaporation of the filtrate, the residue was purified by silica gel column chromatography (EtOAc/MeOH = 95:5), which yielded compound 14b (206 mg, 88%) as an off-white solid. 1 13 1-Hexyl-3-(prop-2-ynyl)urea (17) . Propargylamine (500 μL, 7.80 mmol) was dissolved in anhydrous DCM (20 mL) under an Ar atmosphere, and the resulting yellow solution was cooled to 0°C. Hexyl isocyanate (995 mg, 7.82 mmol) dissolved in 10 mL of anhydrous DCM was added drop-to portionwise, the ice bath was removed, and the reaction mixture was stirred at rt for 45 min. The solvent was evaporated to yield compound 17 (1.39 g, 98%) as an off-white solid, which was used in the following step without further purification. 1 N-(3-(5-(2 0 -Deoxyuridine))prop-2-ynyl)octanamide (18a).
Compound 11a (400 mg, 0.913 mmol), Pd(PPh 3 ) 4 (103 mg, 0.091 mmol), and CuI (35 mg, 0.182 mmol) were dissolved in anhydrous DMF (5 mL) under an Ar atmosphere, and DIPEA (313 μL, 1.82 mmol) and acetylene 15a (496 mg, 2.74 mmol) were then added. After being stirred at rt for 12 h, the solvent was evaporated and coevaporated with xylene. The residue was taken up in DCM/MeOH = 1:1 (20 mL), BioRad XG-X8 (HCO 3 À -form) resin was added, and the mixture was stirred at rt for 30 min. After filtration of the resin and evaporation of the solvents, the crude residue was taken up in EtOAc (30 mL) and the organic layer was washed with brine (3 Â 30 mL), dried over MgSO 4 , and evaporated. The residue was purified by silica gel column chromatography (cyclohexane/EtOAc = 1:1 containing 1% formic acid), and the obtained intermediate was dissolved in dry MeOH (14 mL). NaOMe (30%-solution in MeOH, 265 μL, 1.4 mmol) was added, and the reaction mixture was stirred for 1 h at rt under an Ar atmosphere. The solution was neutralized with Dowex 50WX-8 resin (H þ -form), and the resin was filtered off and washed with MeOH. After evaporation of the filtrate, the residue was purified by silica gel column chromatography (EtOAc/MeOH = 98:2 containing 0.5% formic acid), which yielded compound 18a (251 mg, 68% over 2 steps) as an off-white solid. 1 13 Hz, CH 3 ). 13 N-(3-(5-(2 0 -Deoxyuridine))prop-2-ynyl)butanamide (18c).
Compound 11a (400 mg, 0.913 mmol), Pd(PPh 3 ) 4 (103 mg, 0.091 mmol), and CuI (35 mg, 0.182 mmol) were dissolved in anhydrous DMF (4 mL) under an Ar atmosphere, and DIPEA (313 μL, 1.82 mmol) and then acetylene 15c (343 mg, 2.74 mmol, dissolved in 1 mL anhydrous DMF) were then added. After being stirred at rt for 18 h, the solvent was evaporated and coevaporated with xylene. The residue was taken up in DCM/MeOH = 1:1 (10 mL), BioRad XG-X8 (HCO 3 À form) resin was added, and the mixture was stirred at rt for 30 min. After filtration of the resin and evaporation of the solvents, the crude residue was taken up in EtOAc (30 mL), and the organic layer was washed with brine (3 Â 30 mL), dried over MgSO 4 , and evaporated. The residue was purified by silica gel column chromatography (heptane/EtOAc = 1:2f1:3 each containing 1% formic acid), and the obtained intermediate was dissolved in dry MeOH (14 mL). NaOMe (30% solution in MeOH, 265 μL, 1.4 mmol) was added, and the reaction mixture was stirred for 1 h at rt under an Ar atmosphere. The solution was neutralized with Dowex 50WX-8 resin (H þ -form), and the resin was filtered off and washed with MeOH. After evaporation of the filtrate, the residue was purified by silica gel column chromatography (EtOAc/MeOH = 98:2 containing 1% formic acid), which yielded compound 18c (193 mg, 60% over 2 steps) as an off-white solid. 1 (58 mg, 0.051 mmol), and CuI (20 mg, 0.104 mmol) were dissolved in anhydrous DMF (3 mL) under an Ar atmosphere, and DIPEA (174 μL, 1.01 mmol) and then acetylene 15d (262 mg, 1.51 mmol) were then added. After being stirred at rt for 16 h, the solvent was evaporated and coevaporated with xylene. The residue was taken up in DCM/MeOH = 1:1 (10 mL), BioRad XG-X8 (HCO 3 À -form) resin was added, and the mixture was stirred at rt for 30 min. After filtration of the resin and evaporation of the solvents, the crude residue was purified by a first column of silica gel (DCM/MeOH = 98:2f97:3 each containing 1% formic acid), and the obtained product was subjected to a second short column of silica gel (DCM/MeOH = 95:5 containing 1% formic acid), which yielded compound 23 (118 mg, 53%) as an off-white solid. 1 13 Journal of Medicinal Chemistry ARTICLE N-(3-(5-(3 0 -O-Acetyl-2 0 -deoxyuridine))prop-2-ynyl)heptane-1-sulfonamide (24) . Compound 22 (325 mg, 0.82 mmol), Pd-(PPh 3 ) 4 (91 mg, 0.082 mmol), and CuI (32 mg, 0.164 mmol) were dissolved in anhydrous DMF (4 mL) under an Ar atmosphere, and DIPEA (283 μL, 1.64 mmol) and then acetylene 16 (535 mg, 2.46 mmol) dissolved in anhydrous DMF (1 mL) were added. After being stirred at rt overnight, the solvent was evaporated and coevaporated with xylene. The residue was taken up in DCM/MeOH = 1:1 (10 mL), BioRad XG-X8 (HCO 3 À -form) resin was added, and the mixture was stirred at rt for 30 min. After filtration of the resin and evaporation of the solvents, the crude residue was purified by a first column of silica gel (heptane/EtOAc = 1:1 containing 1% formic acid) and the obtained product was subjected to a second short column of silica gel (DCM/ acetone =85:15 containing 1% formic acid), which yielded compound 24 (225 mg, 57%) as an off-white solid. 1 After being stirred at rt overnight, the solvent was evaporated and coevaporated with xylene. The residue was taken up in DCM/MeOH = 1:1 (10 mL), BioRad XG-X8 (HCO 3 À -form) resin was added, and the mixture was stirred at rt for 30 min. After filtration of the resin and evaporation of the solvents, the crude residue was purified by a first column of silica gel (heptane/EtOAc = 1:2f1:3f1:4 each containing 1% formic acid), and the obtained product was subjected to a second short column of silica gel (DCM/acetone = 80:20f75:25 each containing 1% formic acid), which yielded compound 25 (259 mg) as an oil containing substantial amounts of impurities and was therefore used in the phosphorylation step without any further purification.
General Procedure A 33, 46 for the Phosphorylation of 5-Substituted Derivatives 8, 9aÀb, 18bÀc. An unprotected 5-substituted derivative (1 equiv) was dissolved in PO(OMe) 3 /CH 3 CN = 1:1, and dry pyridine (4.8 equiv) and H 2 O (2.8 equiv) were added and the resulting solution was cooled to 0°C. POCl 3 (4.4 equiv) was added in one portion, and the reaction mixture was stirred at 0°C for 3 h. The reaction mixture was poured into ice/H 2 O and brought to pH 8À9 with NH 4 OH, and then the volatiles were removed in vacuo and the residue was purified by silica gel column chromatography using a gradient of 2-propanol/water/NH 4 OH. The phosphates isolated after lyophilization were further purified by preparative RP-HPLC (C18, 5 μM, 19 mm Â 150 mm) using a gradient of acetonitrile and TEAB (4À10 mM), yielding analytically pure compounds. Next, the phosphates were subjected to ion exchange (Dowex 50 WX-8, Na þ ) and lyophilized, yielding the corresponding disodium salts.
General Procedure B 37,38 for the Phosphorylation of 5-Substituted Derivatives 10aÀb, 14aÀb, 18a. To a solution of an unprotected 5-substituted derivative (1 equiv) and proton sponge (1.5À3 equiv) in trimethyl phosphate was added POCl 3 (1.5À3 equiv) in one portion at 0°C, and the reaction mixture was stirred at 0°C for 2À3 h. The reaction mixture was poured into ice/H 2 O and brought to pH 8À9 with NH 4 OH or 1 M NaOH, and then the volatiles were removed in vacuo and the residue was purified by silica gel column chromatography using a gradient of 2-propanol/water/NH 4 OH. The phosphates isolated after lyophilization were further purified by preparative RP-HPLC (C18, 5 μM, 19 mm Â 150 mm) using a gradient of acetonitrile and TEAB (4À30 mM), yielding analytically pure compounds. Next, the phosphates were subjected to ion exchange (Dowex 50 WX-8, Na þ ) and lyophilized, yielding the corresponding disodium salts.
5-
This compound was prepared according to the general procedure A described above. The reaction mixture was worked up as described above including silica gel column chromatography (2-propanol/NH 4 5-(4-Fluorophenyl)-2 0 -deoxyuridine-5 0 -monophosphate (2a). This compound was prepared according to the general procedure 13 5-Dodecynyl-2 0 -deoxyuridine-5 0 -monophosphate (3a). This compound was prepared according to the general procedure B described above. The following amounts of starting material and reagents were employed: compound 10a (500 mg, 1.29 mmol), POCl 3 (181 μL, 1.94 mmol), and proton sponge (416 mg, 1.94 mmol) in 5 mL of PO(OMe) 3 . The reaction mixture was stirred at 0°C for 2 h and worked up as described above, including silica gel column chromatography (2-propanol/NH 4 was then added, and the reaction mixture was stirred at 40À45°C for 2 days, after which time the solvent was evaporated. The residue was taken up 1 M NaOH (7 mL) and stirred at 100°C for 5 min. The mixture was allowed to cool down to rt and the pH was adjusted to ≈8À9 (dropwise addition of AcOH) and the volatiles were removed in vacuo. The residue was subjected to a column of silica gel (2-PrOH/NH 4 OH/H 2 O = 90:5:5f75:15:10) and to RP-HPLC (C-18, 10 mM aq TEAB/CH 3 CN = 85:15, isocratic, 16 mL/min). Appropriate fractions were pooled and lyophilized, and the obtained product was converted into its disodium salt by passage through a column of Dowex 50-WX8 (Na þ -form) and elution with H 2 O. After evaporation of the solvent and lyophilization, compound 6b (26 mg, 9%) was obtained as a white solid; mp >169°C (dec). 1 Cloning, Expression, and Purification of Mycobacterial ThyX. This was done according to protocols described. 21 ThyX-Inhibition Assay. The tritium-release assay was adapted from Hunter et al. 56 Briefly, the reaction was performed in a final volume of 25 μL, in a 96-well flat bottom plate, including 1.5 μg of M. tuberculosis ThyX, 20 μM homemade mTHF, 10 μM FAD and 500 μM NADPH, and compounds if required. Reaction was initiated by addition of 10 μL of 2 μM [5-3 H] dUMP (13 Ci/mmol). After a 10 min reaction period, at room temperature, the reaction was terminated by the addition of 20 μL of a stop solution (a 3:1 ratio of 2 N TCA:4.3 mM dUMP). To remove unreacted substrates, 150 μL of 10% (w/v) activated charcoal in water was added to the reaction mixture. The plate was incubated on ice for 15 min and then centrifuged at 3800g at 4°C for 10 min. A 100 μL aliquot of the supernatant was assayed by liquid scintillation counting to determine the amount of tritium-containing water produced by the reaction. Percentages of activity compared to control points were calculated and IC 50 values determined.
Cloning, Expression, and Purification of Mycobacterial ThyA. Cloning. PCR reactions were performed using a BioRad MJ Mini Personal Thermal Cycler. Primers were purchased from Eurogentech: 5 0 -CTTGACCATATGGGCCATCATCATCATCATCACG-GCACGCC ATACGAGGACCTGCTG, 5 0 -CTAGTCGGATCCT-CATACCGCGACTGGAGC cDNA containing ThyA gene was used as a template. PCR reactions were carried out using Ex Taq polymerase and standard reaction conditions (Ta 55°C). Reactions were purified using QIAquick PCR purification kit (Qiagen). NdeI and BamHI restrictions enzymes (BioLabs) were used to create sticky ends on the ThyA PCR-fragment, and manufacturer's standard reaction conditions were used. Pet3a vector was also cut with NdeI and BamHI restriction enzymes and treated with alkaline phosphatase. Afterward, pet3a vector was purified from 0.8% agarose gel using QIAEXII Gel extraction kit (Qiagen). Ligation reaction (T4 DNA ligase, BioLabs) was performed according to manufacturer's instructions. TG1 E. coli RbCl chemical competent cells were transformed with the ligation mixture, grown during 1 h at 37°C and 250 rpm in 900 μL LB-medium and then plated on the LB agar plates and grown overnight at 37°C. Several colonies were picked up for colony PCR and also overnight cultures in LB medium were set up. Pet3a plasmid of a positive colony was purified from an overnight culture using QIAprep Spin Miniprep kit (Qiagen), and the concentration was measured using NANODROP 1000.
Expression. BL21 (DE3) pLysS E. coli RbCl chemical competent cells were transformed with pet3a vector containing the ThyA insert, grown during 1 h at 37°C and 250 rpm in 900 μL LB-medium, then plated on the LB-agar plates and grown overnight at 37°C. Afterward, a colony was picked up into an overnight culture. Bacteria from the overnight culture were grown in 1 L LB medium at 37°C and 250 rpm until OD 600 = 0.6À0.8 and then induced with 200 μL 1 M IPTG solution and grown overnight at 22°C and 250 rpm. Bacteria were spun down for 10 min at 10000 rpm and 4°C. The obtained bacterial pellet was stored at À20°C.
Purification. The bacterial pellet was resuspended in 10 mL of lysis buffer containing 5 mg of lysozyme, 1 mM DTT, and protease inhibitor cocktail. After five times, French Press lysate was spun down for 20 min. ThyA protein was purified from supernatants using His6-based affinity Journal of Medicinal Chemistry ARTICLE chromatography (NTA magnetic beads, Qiagen) according to the manufacturer's instructions.
ThyA-Inhibition Assay. ThyA activity was adapted from Kan et al. 58 In brief, the reaction mixture (100 μL) contained 1 μg of ThyA enzyme, 50 mM Tris-HCl (pH 7.5), 500 μM homemade mTHF, 10 mM MgCl 2 , and compound if required. Reactions, performed at room temperature in a 96-well flat bottom plate, were initiated by addition of 20 μL of 2 mM dUMP. The increase in absorbance at 340 nm was measured directly after dUMP addition and after 30 min, using a spectrophotometer (envision, Perkin elmer). Percentages of activity compared to control points (no enzyme, no inhibitor) were calculated and IC 50 values determined.
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